Allocated but not treated: the silent 16

Todd C Lee¹, Andrew M Morris², Ilan S Schwartz³, Emily G McDonald⁴

Affiliations

¹ Division of Infectious Diseases, McGill University, Montreal, QC H4A 3S1, Canada; Clinical Practice Assessment Unit, McGill University, Montreal, QC H4A 3S1, Canada; Department of Medicine and Royal Victoria Hospital, McGill University, Montreal, QC H4A 3S1, Canada. Electronic address: todd.lee@mcgill.ca.
² Division of Infectious Diseases, Department of Medicine, Sinai Health System, Toronto, ON, Canada.
³ Division of Infectious Diseases, Department of Medicine, Faculty of Medicine and Dentistry, University of Alberta, Edmonton, AB, Canada.
⁴ Clinical Practice Assessment Unit, McGill University, Montreal, QC H4A 3S1, Canada; Division of General Internal Medicine, McGill University, Montreal, QC H4A 3S1, Canada; Department of Medicine and Royal Victoria Hospital, McGill University, Montreal, QC H4A 3S1, Canada.

PMID: 35526549
PMCID: PMC9071205
DOI: 10.1016/S0140-6736(22)00377-4

Comment

Allocated but not treated: the silent 16

Todd C Lee et al. Lancet. 2022.

. 2022 May 7;399(10337):1775.

doi: 10.1016/S0140-6736(22)00377-4.

Authors

Todd C Lee¹, Andrew M Morris², Ilan S Schwartz³, Emily G McDonald⁴

Affiliations

¹ Division of Infectious Diseases, McGill University, Montreal, QC H4A 3S1, Canada; Clinical Practice Assessment Unit, McGill University, Montreal, QC H4A 3S1, Canada; Department of Medicine and Royal Victoria Hospital, McGill University, Montreal, QC H4A 3S1, Canada. Electronic address: todd.lee@mcgill.ca.
² Division of Infectious Diseases, Department of Medicine, Sinai Health System, Toronto, ON, Canada.
³ Division of Infectious Diseases, Department of Medicine, Faculty of Medicine and Dentistry, University of Alberta, Edmonton, AB, Canada.
⁴ Clinical Practice Assessment Unit, McGill University, Montreal, QC H4A 3S1, Canada; Division of General Internal Medicine, McGill University, Montreal, QC H4A 3S1, Canada; Department of Medicine and Royal Victoria Hospital, McGill University, Montreal, QC H4A 3S1, Canada.

PMID: 35526549
PMCID: PMC9071205
DOI: 10.1016/S0140-6736(22)00377-4

No abstract available

PubMed Disclaimer

Comment in

Allocated but not treated: the silent 16% - Authors' reply.
Horby P, Staplin N, Emberson J, Haynes R, Landray M. Horby P, et al. Lancet. 2022 May 7;399(10337):1775-1776. doi: 10.1016/S0140-6736(22)00384-1. Lancet. 2022. PMID: 35526547 Free PMC article. No abstract available.

Comment on

Tocilizumab in COVID-19: some clarity amid controversy.
Gupta S, Leaf DE. Gupta S, et al. Lancet. 2021 May 1;397(10285):1599-1601. doi: 10.1016/S0140-6736(21)00712-1. Lancet. 2021. PMID: 33933194 Free PMC article. No abstract available.

References

1. RECOVERY Collaborative Group Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. Lancet. 2021;397:1637–1645. - PMC - PubMed
1. Gupta S, Leaf DE. Tocilizumab in COVID-19: some clarity amid controversy. Lancet. 2021;397:1599–1601. - PMC - PubMed

Publication types

Actions
Actions

MeSH terms

Actions
Actions
Actions

LinkOut - more resources

Full Text Sources
Medical
- MedlinePlus Health Information

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Allocated but not treated: the silent 16

Affiliations

Allocated but not treated: the silent 16

Authors

Affiliations

Comment in

Comment on

Similar articles

References

Publication types

MeSH terms

LinkOut - more resources

Full Text Sources

Medical